Cytoki Pharma ApS: Financial statements 2023
CVR: 40594132
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Cytoki Pharma ApS (CVR 40594132) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -61,547,808 and a net result of DKK -64,519,466 compared with DKK -98,393,590 the year before. Equity in the 2023 report amounted to DKK 66,697,075. The solvency ratio was 90.2%. The company had 5 employees in the financial year.
- Gross Profit
- DKK -61,547,808
- Profit/Loss
- DKK -64,519,466
- Equity
- DKK 66,697,075
- Total Assets
- DKK 73,926,611
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -61.5 mio. | -64.5 mio. | 66.7 mio. | 5 |
| 2022 | - | -98.8 mio. | -98.4 mio. | 51.2 mio. | 4 |
| 2021 | - | -32 mio. | -29.8 mio. | 106.8 mio. | 3 |
| 2020 | - | -6 mio. | -6.8 mio. | -9.8 mio. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of July 17, 2023, Annegret Elisabeth De Baey-Diepolder has joined the board of directors of Cytoki Pharma ApS.
As of July 17, 2023, Amanda Viven Gett-Chaperot has left the board of directors of Cytoki Pharma ApS.
Cytoki Pharma ApS has published its annual report for 2022. Gross profit came to DKK -98,763,646, and the net result was DKK -98,393,590.
On May 16, 2023, the company changed its name from CytoKi Pharma ApS to Cytoki Pharma ApS.
About Cytoki Pharma ApS
Cytoki Pharma ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is in liquidation. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CytoKi Pharma ApS. The management consists of Anders Hagstrøm. The company's owners include LUNDBECKFOND INVEST A/S, 15-Bio ApS and YSIOS Biofund III, F.C.R.E. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -42,198,706 and a net result of DKK -43,800,007 compared with DKK -39,261,697 the year before. Equity in the 2025 report amounted to DKK 13,473,548.